Details for New Drug Application (NDA): 207411

NDA 207411 describes AZELASTINE HYDROCHLORIDE, which is a drug marketed by Alembic, Apotex Inc, Epic Pharma Llc, Gland Pharma Ltd, Sandoz, Somerset Theraps Llc, Sun Pharm, Alkem Labs Ltd, Amneal, Aurobindo Pharma Ltd, Bionpharma, Hikma, Padagis Israel, Sciegen Pharms Inc, Upsher Smith Labs, Zydus Pharms, and Apotex, and is included in twenty-eight NDAs. It is available from nineteen suppliers. Additional details are available on the AZELASTINE HYDROCHLORIDE profile page.

The generic ingredient in AZELASTINE HYDROCHLORIDE is azelastine hydrochloride; fluticasone propionate. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride; fluticasone propionate profile page.

Summary for 207411

Tradename:	AZELASTINE HYDROCHLORIDE
Applicant:	Somerset Theraps Llc
Ingredient:	azelastine hydrochloride
Patents:	0

Pharmacology for NDA: 207411

Mechanism of Action

Histamine H1 Receptor Antagonists

Suppliers and Packaging for NDA: 207411

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	207411	ANDA	Somerset Therapeutics, LLC	70069-091	70069-091-01	1 BOTTLE in 1 CARTON (70069-091-01) / 6 mL in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION/DROPS;OPHTHALMIC			Strength	0.05%
Approval Date:	Mar 29, 2019	TE:	AT	RLD:	No

Complete Access Available with Subscription